Rabeprazole sodium

Rabeprazole sodium (CAS 117976-90-6), also marketed under the brand name Aciphex, is a proton pump inhibitor used as an active pharmaceutical ingredient in the treatment of acid-related gastrointestinal disorders. It functions by suppressing gastric acid secretion, making it a key API in finished dosage form manufacturing. Rabeprazole sodium is formulated into enteric-coated tablets and delayed-release capsules.

It is used for the management of conditions such as GERD, peptic ulcers, and Zollinger-Ellison syndrome. Contract manufacturers and generic drug producers source it as a primary API for solid oral dosage forms. The material targets the gastrointestinal therapeutic segment and is also used in combination therapy formulations. It is particularly effective alongside antibiotics for H. pylori eradication regimens.

Pharmaceutical formulators evaluating bioequivalence studies or generic product development will source this material to established reference standards. It is supplied as a white to off-white crystalline powder. It is available in pharmaceutical-grade specifications, with material typically conforming to USP, BP, or in-house pharmacopoeial standards depending on the supplier requirements.

Packaging is offered in controlled quantities suitable for R&D through to commercial-scale API manufacturing. This ensures stability and compliance for global pharmaceutical supply chains and production.